|Articles|December 30, 2015

ACRES and ActivMed Collaborate on Clinical Research Site Standards and Sustainability

The Alliance for Clinical Research Excellence and Safety (ACRES) and ActivMed Practices & Research, Inc., partner on clinical research site standards, accreditation and training as well as community-based site development programs.

The Alliance for Clinical Research Excellence and Safety (ACRES), a Massachusetts-based non-profit organization building a global system for clinical research and ActivMed Practices & Research, Inc., a woman-owned, for-profit, multi-specialty, free standing research organization based in Massachusetts and New Hampshire, today announced a strategic alliance focused on enhancing quality and sustainability of clinical research sites.  ActivMed will participate in ACRES ongoing Site Accreditation and Standards Initiative (SASI) to improve performance of global research sites through shared standards, accreditation, training and support.   ActivMed participation will start with membership in a Phase 3 standards domain team involving personnel and professionalism criteria.

With access to nearly one million patients in the Northeast region and a full range of clinical research studies (Phase I, II, III, IIIb and IV) performed on an inpatient and outpatient basis, ActivMed will also collaborate with ACRES in the testing of developed standards and processes for ACRES site accreditation work, including ACRES innovative ‘dynamic accreditation’ approach.  Other areas of shared interest include professional development programs for research staff that can be offered within local communities as well as on line and the development of education and training programs ongoing at reasonable costs.

Terry Stubbs, ActivMed Founder, President and CEO, who has successfully conducted more than 735 clinical research studies during her 25 years in healthcare research, expressed her excitement, noting, “The creation of a systems-based approach to promote high-performing clinical research sites and to properly reward the work they do is long-overdue.  The value proposition is clear--we believe this is a terrific opportunity for sites committed to quality, like ActivMed, to get involved and to have real impact.”

“We are delighted that a growing number of sites and site-organizations world-wide are aligning with the ACRES vision,” added Greg Koski, ACRES Co-founder and CEO. “ActivMed is committed to quality in every dimension of its work in clinical research, and it now brings this commitment to this global collaboration.”

ACRES
The Alliance for Clinical Research Excellence and Safety (ACRES) is a non-profit multi-sector alliance working in the public interest. It brings together diverse stakeholders across clinical research, harnesses their expertise to collaboratively build an open, integrated global system based in principles of Accountable Research™ and adapts lessons from industries that successfully implemented principles of systems and safety engineering, such as transportation, communications and information technology.


ActivMed
ActivMed Practices & Research, Inc. was founded in 1994 and is headquartered in Methuen, Massachusetts. The Company operates three clinical research offices:  Two within Massachusetts, Methuen and the newest location just opened in Beverly MA.  They also have an office located in Newington, New Hampshire. Having successfully completed over 700 clinical research trials, nationally recognized ActivMed Practices & Research, Inc. has developed the staff, processes, recruitment practices and facilities to exceed performance expectations for Phase I, II, III and IV clinical trials.  The Company has been recognized for excellence in patient care, patient recruitment and a high standard of protocol delivery.
 


Related to this article

The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.